ArticleTranslational cancer research2026
Survival outcomes by molecular subtypes based on receptor status in medullary breast carcinoma: a SEER database analysis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medullary breast carcinoma (MBC) is a rare histological subtype of invasive breast cancer. This study aimed to compare prognostic outcomes between MBC and invasive breast carcinoma of no special type (IBC-NST; the most prevalent histological category), and to further evaluate survival differences among molecular subtypes of MBC. Methods: Clinical and survival data for patients with MBC and IBC-NST were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was used to reduce confounding effects. Survival comparisons were performed using the log-rank test. MBC cases were categorized into triple-negative breast cancer (TNBC), luminal, and human epidermal growth factor receptor 2 (HER2)-overexpressing subtypes based on receptor status. Prognostic variations among these molecular subgroups were similarly analyzed. Cox regression was employed to identify independent prognostic factors in MBC. Results: Compared to IBC-NST patients, those with MBC were generally younger, had higher tumor grade, larger tumor size (predominantly T2 stage), higher frequency of estrogen receptor (ER)/progesterone receptor (PR)/HER2 negativity, and lower lymph node involvement. Both before and after PSM, MBC patients exhibited significantly better overall survival (OS) and breast cancer-specific survival (BCSS) than IBC-NST patients. Multivariate analysis identified age, tumor (T) stage, node (N) stage, and chemotherapy as independent prognostic factors for MBC. However, no significant survival differences were observed among molecular subtypes of MBC. Conclusions: Despite presenting with more aggressive clinicopathological characteristics, MBC patients had a more favorable prognosis compared to those with IBC-NST. Molecular subtype was not associated with significant survival differences in MBC. Key determinants of survival in MBC included age, T stage, N stage, and chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.